AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%
Last update at 2025-04-17T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
Thu 10 Apr 25, 03:03 PMSeeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy
Thu 10 Apr 25, 10:18 AMAxsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
Tue 08 Apr 25, 11:00 AMWhy Shares of Axsome Therapeutics Slumped Today
Tue 01 Apr 25, 05:23 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -187.13365M | -130.40299M | -102.90060M | -68.34519M | -30.96546M |
| Minority interest | - | - | - | - | - |
| Net income | -197.76648M | -134.94339M | -105.38872M | -69.68684M | -30.96546M |
| Selling general administrative | 159.25M | 66.65M | 28.90M | 13.60M | 9.35M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 44.84M | - | - | - | 0.00000M |
| Reconciled depreciation | 4.14M | 1.16M | 0.08M | 0.04M | 0.05M |
| Ebit | -176.50082M | -125.86259M | -99.14133M | -67.24510M | -32.67809M |
| Ebitda | -170.93665M | -124.70693M | -99.08775M | -67.10565M | -32.62916M |
| Depreciation and amortization | 5.56M | 1.16M | 0.05M | 0.14M | 0.05M |
| Non operating income net other | - | -5.69606M | -3.81285M | -1.23954M | 1.66M |
| Operating income | -176.50082M | -124.70693M | -99.14133M | -67.24510M | -32.84658M |
| Other operating expenses | 226.54M | 124.71M | 99.09M | 67.11M | 32.63M |
| Interest expense | 7.33M | 5.70M | 2.57M | 1.24M | 1.13M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | 1.24M | 1.66M |
| Net interest income | -7.33460M | -5.69606M | -2.56584M | -1.23954M | -1.12731M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 10.63M | 4.54M | 2.49M | 1.34M | 3.01M |
| Total revenue | 50.04M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 221.34M | 124.71M | 99.09M | 67.11M | 32.63M |
| Cost of revenue | 5.20M | - | - | - | 0.00000M |
| Total other income expense net | -10.63283M | -5.69606M | -3.75927M | -1.10009M | 2.79M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -187.13365M | -130.40299M | -102.95418M | -68.34519M | -30.96546M |
| Net income applicable to common shares | -187.13365M | -130.40299M | -102.90060M | -68.34519M | -30.96546M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 588.24M | 331.48M | -338.35658M | 186.13M | 220.55M |
| Intangible assets | 53.29M | 59.66M | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 8.12M | 2.78M | 0.05M | 0.15M | 0.41M |
| Total liab | 397.26M | 221.92M | 70.84M | 72.34M | 41.83M |
| Total stockholder equity | 190.98M | 109.56M | -409.19909M | -278.79609M | -175.89549M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 96.91M | 57.53M | 9.30M | 8.71M | 0.68M |
| Common stock | 0.00500M | 0.00435M | 0.00378M | 0.00374M | 0.00369M |
| Capital stock | 0.00500M | 0.00435M | 0.00378M | 0.00374M | 0.00369M |
| Retained earnings | -835.57100M | -596.33274M | -409.19909M | -278.79609M | -175.89549M |
| Other liab | - | 31.10M | - | - | - |
| Good will | 12.04M | 10.31M | - | - | - |
| Other assets | - | 14.72M | -426.14164M | 2.11M | 0.14M |
| Cash | 386.19M | 200.84M | 86.47M | 183.88M | 219.97M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 138.85M | 96.56M | 23.07M | 23.44M | 24.49M |
| Current deferred revenue | - | - | - | - | 10.27M |
| Net debt | -199.82100M | -106.15839M | -36.76266M | -133.75231M | -200.03125M |
| Short term debt | 1.27M | 0.42M | 0.62M | 1.22M | 2.60M |
| Short long term debt | - | - | - | - | 2.60M |
| Short long term debt total | 186.37M | 94.68M | 49.71M | 50.12M | 19.93M |
| Other stockholder equity | 1026.54M | 705.88M | -0.00378M | -0.00374M | -0.00369M |
| Property plant equipment | - | 1.14M | 0.28M | 0.05M | 0.03M |
| Total current assets | 504.26M | 245.64M | 86.52M | 184.02M | 220.38M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 39.59M | 15.63M | 113.79M | 178.72M |
| Short term investments | - | - | - | - | - |
| Net receivables | 94.82M | 37.70M | - | - | - |
| Long term debt | 178.07M | 94.26M | 49.09M | 48.32M | 17.33M |
| Inventory | 15.13M | 4.32M | - | - | - |
| Accounts payable | 40.68M | 38.61M | 13.15M | 13.50M | 10.94M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.00378M | 0.00374M | 0.00369M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -409.19909M | -278.79609M | -175.90000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 11.03M | 14.72M | 0.32M | 0.32M | 0.14M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 83.97M | 85.83M | 1.27M | 2.11M | 0.17M |
| Capital lease obligations | 8.30M | 0.42M | 0.62M | 1.80M | - |
| Long term debt total | - | - | 49.09M | 48.32M | 17.33M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -53.70211M | -0.30755M | -0.04589M | -0.01612M | -0.03270M |
| Change to liabilities | 25.46M | 0.23M | 0.32M | 14.36M | 1.42M |
| Total cashflows from investing activities | -53.70211M | -0.30755M | -0.04589M | -0.01612M | -0.03270M |
| Net borrowings | 45.00M | -0.30934M | 27.24M | 12.76M | -3.35933M |
| Total cash from financing activities | 284.58M | 11.13M | 42.41M | 252.39M | 10.03M |
| Change to operating activities | 37.24M | 0.68M | -2.14866M | 7.91M | 1.27M |
| Net income | -187.13365M | -130.40299M | -102.90060M | -68.34519M | -30.96546M |
| Change in cash | 114.37M | -97.40360M | -36.08971M | 206.00M | -20.05238M |
| Begin period cash flow | 86.47M | 183.88M | 219.97M | 13.97M | 34.02M |
| End period cash flow | 200.84M | 86.47M | 183.88M | 219.97M | 13.97M |
| Total cash from operating activities | -116.51080M | -108.22576M | -78.45657M | -46.37506M | -30.05370M |
| Issuance of capital stock | 236.79M | 7.21M | 14.13M | 238.23M | 12.88M |
| Depreciation | 5.56M | 1.16M | 0.08M | 0.04M | 0.05M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -5.27511M | -1.33092M | -1.33092M | -1.33092M | - |
| Change to account receivables | -37.69887M | -37.69887M | -37.69887M | -37.69887M | - |
| Sale purchase of stock | - | 11.61M | 15.18M | 239.63M | 13.39M |
| Other cashflows from financing activities | 47.79M | 3.92M | 49.95M | 21.39M | 0.49M |
| Change to netincome | 39.91M | 20.80M | 16.00M | 6.12M | -1.03603M |
| Capital expenditures | 0.70M | 0.31M | 0.05M | 0.02M | 0.03M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | -0.00475M | 7.31M | 0.81M | 0.11M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -97.40360M | -36.08971M | 206.00M | -20.05238M |
| Change in working capital | 23.67M | 0.32M | 0.41M | 15.17M | 1.52M |
| Stock based compensation | 37.73M | 20.80M | 14.76M | 6.12M | 1.75M |
| Other non cash items | 3.66M | -0.10461M | 7.95M | 0.65M | 0.38M |
| Free cash flow | -117.21291M | -108.53331M | -78.50246M | -46.39118M | -30.08640M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics Inc |
-0.01 0.0096% | 104.46 | - | - | 14.28 | 52.22 | 13.93 | -14.8071 |
| NVO Novo Nordisk A/S |
-4.8 7.63% | 58.08 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.79 4.46% | 59.70 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.21 0.66% | 489.10 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
13.88 2.53% | 563.16 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
One World Trade Center, New York, NY, United States, 10007
| Name | Title | Year Born |
|---|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & Pres | 1968 |
| Mr. Nick Pizzie CPA, M.B.A. | Chief Financial Officer | 1975 |
| Mr. Mark L. Jacobson | COO & Sec. | 1983 |
| Mr. Hunter Murdock Esq. | Exec. VP of Legal & Compliance | NA |
| Dr. Amanda Jones Pharm.D. | Sr. VP of Clinical Devel. | 1983 |
| Ms. Lori Englebert M.B.A. | Exec. VP of Commercial & Bus. Devel. | 1978 |
| Mr. Kevin Laliberte Pharm.D. | Exec. VP of Product Strategy | 1978 |
| Joseph Debrah-Afful CPA, M.B.A. | Director of Fin. | NA |
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & President | 1968 |
| Mr. Mark L. Jacobson | COO & Secretary | 1983 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...